Synaptiflora offers an AI-driven microbiome analytics platform aimed at accelerating drug development. The system integrates microbiome composition, metabolomics, and host data via a foundational AI model—SynaptiCore—enabling disease-specific modules for applications like trial optimization and biomarker discovery By translating complex biological data into actionable insights, the platform helps pharmaceutical companies predict patient response, improve stratification, and reduce trial failures. Synaptiflora focuses on oncology and immunology use cases, built from a proprietary microbiome dataset and validated through a proof-of-concept for colorectal cancer with around 90% accuracy in predicting non-responders—claiming the ability to accelerate trials and increase drug efficacy.